ORMDL3 and hepatocellular carcinoma: By using sorafenib (4 μM) treatment, as compared to the control group, Cleaved Caspase 9, Cleaved Caspase 3, and Cleaved PARP expressions were increased in ORMDL3-silenced HCC cells.